Gastrointestinal parasitic infection symptoms include abdominal pain, diarrhea, dysentery, flatulence, malabsorption and symptoms of biliary obstruction.
It can be caused by protozoan parasites and helminths.
Host susceptibility factors in gastrointestinal parasitic infections are nutritional status, intercurrent disease, pregnancy, immunosuppressive drugs and presence of a malignancy.
Knowledge of the geographic distribution of parasites is helpful in the diagnosis of patients.

Parasitic Infections Drug Information

Drug Information

Indication: Upper & lower resp tract infections, skin & soft tissue infections, ENT infections, UTI.

Indication: Bronchitis, community-acquired pneumonia, sinusitis, pharyngitis, otitis media, skin & soft tissue infecti...

Indication: Urogenital trichomoniasis in both genders. All forms of amoebiasis (intestinal & extraintestinal disease &...

Indication: Amoebic liver abscess, anaerobic bacterial infections. Tab: Symptomatic & asymptomatic trichomoniasis, int...

Indication: Appendicitis, cholecystitis, peritonitis, liver, lung & brain abscess, post-op wound infection; puerperal ...

Pharmaniaga Erythromycin Suspension
erythromycin ethylsuccinate

Indication: Infections due to susceptible organisms.

Indication: Trichomoniasis in males & females; amoebiasis, vag, intra-abdominal, skin, gynaecologic, bone & joint ...

Indication: Whipworm, pinworm, hookworm & roundworm infestation.

Retorin Suspension
erythromycin ethylsuccinate

Indication: GUT infection, pneumonia, diphteria, erythrasma, gonorrhoea, Legionnaires' disease, listeria infection, pertus...

Indication: Roundworm, whipworm, pinworm or threadworm, hookworm, Strongyloides stercoralis, Taenia solium, Taenia saginat...

2  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 16 Feb 2021

Infigratinib may be a suitable second- or later-line treatment option for patients with advanced or metastatic cholangiocarcinoma (CCA) with FGFR2* fusions or rearrangements, according to interim results of a phase II, open-label, single-arm study presented at ASCO GI 2021.